Abstract
Introduction: Patients with advanced pancreatic cancer have a poor prognosis. FOLFIRINOX (FFX) and gemcitabine plus nab-paclitaxel (GnP) have been established as first-line treatment, but they have not been confirmed as second-line treatment after FFX. The aim of this study was to evaluate the safety and efficacy of GnP as second-line therapy after FFX in patients with unresectable pancreatic cancer. Methods: Twenty-five patients with unresectable pancreatic cancer were enrolled. The patients were treated with GnP after FFX between September 2015 and September 2019. Tumor response, progression-free survival (PFS), overall survival (OS), and incidence of adverse events were evaluated. Results: The response rate, disease control rate, median PFS, and median OS were 12%, 96%, 5.3 months, and 15.6 months, respectively. The common grade 3 or 4 adverse events were neutropenia (76%) and anemia (16%). Conclusions: GnP after FOLFIRINOX is expected to be one of the second-line recommendations for patients with unresectable pancreatic cancer.
References
1.
Cancer Registry and Statistics
. Cancer information service
. Japan
: National Cancer Center
.2.
Hruban
RH
. Pancreatic cancer
. In: World cancer report 2014
. Geneva, Switzerland
: World Heath Organization
; 2014
. p. 413
–21
.3.
Conroy
T
, Desseigne
F
, Ychou
M
, Bouché
O
, Guimbaud
R
, Bécouarn
Y
, FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer
. N Engl J Med
. 2011 May 12
;364
(19
):1817
–25
. .4.
Von Hoff
DD
, Ervin
T
, Arena
FP
, Chiorean
EG
, Infante
J
, Moore
M
, Increased survival in pancreatic cancer with nab-paclitaxel plus gemcitabine
. N Engl J Med
. 2013 Oct 31
;369
(18
):1691
–703
. .5.
Chiorean
EG
, Cheung
WY
, Giordano
G
, Kim
G
, Al-Batran
SE
. Real-world comparative effectiveness of nab-paclitaxel plus gemcitabine versus FOLFIRINOX in advanced pancreatic cancer: a systematic review
. Ther Adv Med Oncol
. 2019
;11
:1758835919850367
. .6.
Oettle
H
, Riess
H
, Stieler
JM
, Heil
G
, Schwaner
I
, Seraphin
J
, Second-line oxaliplatin, folinic acid, and fluorouracil versus folinic acid and fluorouracil alone for gemcitabine-refractory pancreatic cancer: outcomes from the CONKO-003 trial
. J Clin Oncol
. 2014 Aug 10
;32
(23
):2423
–9
. .7.
Wang-Gillam
A
, Li
CP
, Bodoky
G
, Dean
A
, Shan
YS
, Jameson
G
, Nanoliposomal irinotecan with fluorouracil and folinic acid in metastatic pancreatic cancer after previous gemcitabine-based therapy (NAPOLI-1): a global, randomised, open-label, phase 3 trial
. Lancet
. 2016 Feb 6
;387
(10018
):545
–57
. .8.
Salem
ME
, Alistar
AT
, Dyson
G
, Stanski
N
, Mahaseth
H
, Choi
M
, Albumin-bound paclitaxel plus Gemcitabine after first-line FOLFIRINOX therapy in patients with pancreatic cancer
. J Clin Oncol
. 2014
;32
(15_suppl
):e15252
. abstract e15252. .9.
Portal
A
, Pernot
S
, Tougeron
D
, Arbaud
C
, Bidault
AT
, de la Fouchardière
C
, Nab-paclitaxel plus gemcitabine for metastatic pancreatic adenocarcinoma after Folfirinox failure: an AGEO prospective multicentre cohort
. Br J Cancer
. 2015 Sep 29
;113
(7
):989
–95
. .10.
Zhang
Y
, Hochster
H
, Stein
S
, Lacy
J
. Gemcitabine plus nab-paclitaxel for advanced pancreatic cancer after first-line FOLFIRINOX: single institution retrospective review of efficacy and toxicity
. Exp Hematol Oncol
. 2015
;4
:29
. .11.
Chan
EM
, Hong
TS
, Clark
JW
, Blaszkowsky
LS
, Allen
JN
, Zhu
A
, Gemcitabine (G) + nab-paclitaxel (nab-P) versus G in patients (pts) with advanced pancreatic cancer (PDAC) after FOLFIRINOX: a single center, retrospective review
. J Clin Oncol
. 2016 Feb 1
;34
(4_suppl
):348
. .12.
Nguyen
KT
, Kalyan
A
, Beasley
HS
, Singhi
AD
, Sun
W
, Zeh
HJ
, Gemcitabine/nab-paclitaxel as second-line therapy following FOLFIRINOX in metastatic/advanced pancreatic cancer-retrospective analysis of response
. J Gastrointest Oncol
. 2017 Jun
;8
(3
):556
–65
. .13.
Rassy
E
, Assi
T
, El Karak
F
, Ghosn
M
, Kattan
J
. Could the combination of nab-paclitaxel plus Gemcitabine salvage metastatic pancreatic adenocarcinoma after folfirinox failure? A single institutional retrospective analysis
. Clin Res Hepatol Gastroenterol
. 2017
;41
:e26
–e28
.14.
Aung
KL
, Creighton
S
, Fraser
A
, Dodd
A
, Moura
S
, Albaba
H
, Overall survival (OS) achieved with gemcitabine (G) or gemcitabine-abraxane (GA) in patients (pts) with advanced pancreatic ductal adenocarcinoma (PDAC) who received first line modified FOLFIRINOX (m-FFX) palliative chemotherapy
. J Clin Oncol
. 2017 May 30
(15 suppl
).15.
Vendrell
I
, Ferreira
AR
, Pulido
C
, Parmanande
A
, Silva
FFD
, Barreira
JV
, Retrospective multicenter cohort of nab-paclitaxel plus gemcitabine (NG) after FOLFIRINOX failure in advanced pancreatic cancer (APC): effectiveness, tolerability, and response markers
. J Clin Oncol
. 2017 May 30
(15 suppl
).16.
Zhang
H
, Kellett
C
, Lambert
P
, Kim
CA
. Efficacy and tolerability of second-line nab-paclitaxel and gemcitabine after failure of first-line FOLFIRINOX for advanced pancreas cancer: a single-institution experience
. Clin Colorectal Cancer
. 2018 Sep
;17
(3
):e451
–e56
. .17.
Ozaka
M
, Sasaki
T
, Yamada
I
, Kanata
R
, Akiyama
D
, Katagiri
T
, Second-line treatment of modified FOLFIRINOX or nab-paclitaxel plus gemcitabine for metastatic pancreatic adenocarcinoma
. J Clin Oncol
. 2018 Feb 26
;36
(4_suppl
):458
. .18.
Vogl
UM
, Andalibi
H
, Klaus
A
, Vormittag
L
, Schima
W
, Heinrich
B
, Nab-paclitaxel and gemcitabine or FOLFIRINOX as first-line treatment in patients with unresectable adenocarcinoma of the pancreas: does sequence matter?
BMC Cancer
. 2019 Jan 8
;19
(1
):28
. .19.
Mita
N
, Iwashita
T
, Uemura
S
, Yoshida
K
, Iwasa
Y
, Ando
N
, Second-line gemcitabine plus nab-paclitaxel for patients with unresectable advanced pancreatic cancer after first-line FOLFIRINOX failure
. J Clin Med
. 2019 May 29
;8
(6
):761
. .20.
Eisenhauer
EA
, Therasse
P
, Bogaerts
J
, Schwartz
LH
, Sargent
D
, Ford
R
, New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1)
. Eur J Cancer
. 2009 Jan
;45
(2
):228
–47
. .21.
Fernandes
BM
, Bitton
RC
, Sabbaga
J
, Hoff
PM
. Is Gemcitabine effective for pancreatic cancer after progression to FOLFIRINOX?
J Clin Oncol
. 2017
;35
(4_suppl
):489
. abstract 489. .22.
Gilabert
M
, Chanez
B
, Rho
YS
, Giovanini
M
, Turrini
O
, Batist
G
, Evaluation of Gemcitabine efficacy after the FOLFIRINOX regimen in patients with advanced pancreatic adenocarcinoma
. Medicine
. 2017
;96
:e6544
. .23.
Lino
ADR
, Abrahao
CM
, Brandao
RM
, Gomes
JR
, Ferrian
AM
, Machado
MCC
, Role of Gemcitabine as second-line therapy after progression on FOLFIRINOX in advanced pancreatic cancer: a retrospective analysis
. J Gastrointest Oncol
. 2015
;6
:511
–5
.24.
Sarabi
M
, Mais
L
, Oussaid
N
, Desseigne
F
, Guibert
P
, De La Fouchardiere
C
. Use of Gemcitabine as a second-line treatment following chemotherapy with folfirinox for metastatic pancreatic adenocarcinoma
. Oncol Lett
. 2017
;13
:4917
–24
. .25.
Viaud
J
, Brac
C
, Artru
P
, Le Pabic
E
, Leconte
B
, Bodère
A
, Gemcitabine as second-line chemotherapy after Folfirinox failure in advanced pancreatic adenocarcinoma: a retrospective study
. Dig Liver Dis
. 2017
;49
:692
–6
. .26.
Ueno
H
, Ikeda
M
, Ueno
M
, Mizuno
N
, Ioka
T
, Omuro
Y
, Phase I/II study of nab-paclitaxel plus gemcitabine for chemotherapy-naive Japanese patients with metastatic pancreatic cancer
. Cancer Chemother Pharmacol
. 2016 Mar
;77
(3
):595
–603
. .27.
Okusaka
T
, Ikeda
M
, Fukutomi
A
, Ioka
T
, Furuse
J
, Ohkawa
S
, Phase II study of FOLFIRINOX for chemotherapy-naïve Japanese patients with metastatic pancreatic cancer
. Cancer Sci
. 2014 Oct
;105
(10
):1321
–6
. .28.
Bauer
TM
, El-Rayes
BF
, Li
X
, Hammad
N
, Philip
PA
, Shields
AF
, Carbohydrate antigen 19-9 is a prognostic and predictive biomarker in patients with advanced pancreatic cancer who receive gemcitabine-containing chemotherapy: a pooled analysis of 6 prospective trials
. Cancer
. 2013 Jan 15
;119
(2
):285
–92
. .29.
Maisey
NR
, Norman
AR
, Hill
A
, Massey
A
, Oates
J
, Cunningham
D
. CA19-9 as a prognostic factor in inoperable pancreatic cancer: the implication for clinical trials
. Br J Cancer
. 2005 Oct 3
;93
(7
):740
–3
. .30.
Saad
ED
, Machado
MC
, Wajsbrot
D
, Abramoff
R
, Hoff
PM
, Tabacof
J
, Pretreatment CA 19-9 level as a prognostic factor in patients with advanced pancreatic cancer treated with gemcitabine
. Int J Gastrointest Cancer
. 2002
;32
(1
):35
–41
. .© 2021 S. Karger AG, Basel
2021
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.
